Biomx INC 10-Q quarterly reports

BiomX Inc. reports Q1 2026 results following a strategic pivot from clinical-stage biopharma to defense and security technology.

BiomX reported a significant increase in net loss for Q3 2025, alongside a going concern warning, while its lead cystic fibrosis program faced an FDA clinical hold.

BiomX Inc. reported increased net losses and a significant decline in cash, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial results for its lead programs.

BiomX Inc. reports its financial results for the quarter ended March 31, 2025, highlighting progress in its clinical programs and recent financing activities.

BiomX Inc. reports a net loss of $9.6 million for the third quarter of 2024, alongside updates on clinical trial progress and a reverse stock split.

BiomX Inc. reported its financial results for the second quarter of 2024, showcasing advancements in its clinical programs and the impact of the Adaptive Phage Therapeutics acquisition.

BiomX Inc. reports a net loss of $17.3 million for the first quarter of 2024, alongside the completion of the Adaptive Phage Therapeutics acquisition and a $50 million private placement.